Latest News and Press Releases

Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q3 2022 interim report on Wednesday 23 November 2022, 08:30am – 09:30am CET (local time). ...

Borkenholm AS has on 8 September 2022 purchased 4,000 shares in PCI Biotech Holding ASA ("PCI Biotech") at an average price of NOK 1.948 per share. Borkenholm AS is a related party to board member...

Borkenholm AS has on 8 September 2022 purchased 4,000 shares in PCI Biotech Holding ASA ("PCI Biotech") at an average price of NOK 1.948 per share. Borkenholm AS is a related party to board member...

Oslo (Norway), 31 August 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and...

Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year 2022 interim report on Wednesday 31 August 2022, 08:30am – 09:30am CEST...

Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the...

Oslo, 25 May 2022. The Annual General Meeting in PCI Biotech Holding ASA took place today, 25 May 2022. All proposals were resolved by the Annual General Meeting as presented in the notice convening...

Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo (Norway), 11 May 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2022 results. Please find enclosed the report and presentation. ...

Oslo (Norway), 9 May 2022 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced a...